Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.

Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.

Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.

Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.

Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).

Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.

Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.

Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.

Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.

Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).

Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.

Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.

Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.

Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.

Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).

Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.

Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.

Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.

Key clinical point: The risk for the first and metachronous colorectal cancer (CRC) was considerably different in patients with Lynch syndrome (LS), Lynch-like syndrome (LLS), and familial colorectal cancer type X (FCCX), with the risk being highest in LS.

Major finding: Compared with LS, the cumulative CRC risk was significantly lower in FCCX without (hazard ratio [HR], 0.13; 95% confidence interval [CI], less than 0.01-0.95) and with (HR, 0.19; 95% CI, 0.02-0.69) previous CRC. In addition, CRC risk was significantly lower in the group of patients with LLS with a previous CRC than LS group (HR, 0.54; 95% CI, 0.30-0.92).

Study details: Findings are from a prospective analysis of 1,448 patients who were classified as having FCCX (n=103), LLS (n=481), or LS (n=864).

Disclosures: This study was supported by grants from the German Cancer Aid. D Vangala declared receiving speaker’s honoraria, travel support, and congress registration fees from various sources. All other authors declared no conflict of interests.

Source: Bucksch K et al. Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33790.

Key clinical point: The risk for the first and metachronous colorectal cancer (CRC) was considerably different in patients with Lynch syndrome (LS), Lynch-like syndrome (LLS), and familial colorectal cancer type X (FCCX), with the risk being highest in LS.

Major finding: Compared with LS, the cumulative CRC risk was significantly lower in FCCX without (hazard ratio [HR], 0.13; 95% confidence interval [CI], less than 0.01-0.95) and with (HR, 0.19; 95% CI, 0.02-0.69) previous CRC. In addition, CRC risk was significantly lower in the group of patients with LLS with a previous CRC than LS group (HR, 0.54; 95% CI, 0.30-0.92).

Study details: Findings are from a prospective analysis of 1,448 patients who were classified as having FCCX (n=103), LLS (n=481), or LS (n=864).

Disclosures: This study was supported by grants from the German Cancer Aid. D Vangala declared receiving speaker’s honoraria, travel support, and congress registration fees from various sources. All other authors declared no conflict of interests.

Source: Bucksch K et al. Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33790.

Key clinical point: The risk for the first and metachronous colorectal cancer (CRC) was considerably different in patients with Lynch syndrome (LS), Lynch-like syndrome (LLS), and familial colorectal cancer type X (FCCX), with the risk being highest in LS.

Major finding: Compared with LS, the cumulative CRC risk was significantly lower in FCCX without (hazard ratio [HR], 0.13; 95% confidence interval [CI], less than 0.01-0.95) and with (HR, 0.19; 95% CI, 0.02-0.69) previous CRC. In addition, CRC risk was significantly lower in the group of patients with LLS with a previous CRC than LS group (HR, 0.54; 95% CI, 0.30-0.92).

Study details: Findings are from a prospective analysis of 1,448 patients who were classified as having FCCX (n=103), LLS (n=481), or LS (n=864).

Disclosures: This study was supported by grants from the German Cancer Aid. D Vangala declared receiving speaker’s honoraria, travel support, and congress registration fees from various sources. All other authors declared no conflict of interests.

Source: Bucksch K et al. Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33790.

Key clinical point: Low skeletal muscle area (SMA) and high visceral to total fat ratio were associated with worse outcomes in patients with nonmetastatic colon cancer who presented for elective resection.

Major finding: The risk for 5-year cancer recurrence after surgery was significantly higher in patients with low SMA (hazard ratio [HR], 2.30; P = .04) and high visceral to total fat ratio (HR, 5.78; P = .02). Even the risk of developing a 30-day infective complication was significantly higher in patients with low SMA (odds ratio [OR], 2.13; P = .004) and high visceral to total fat ratio (OR, 3.20; P = .01).

Study details: Findings are from a translational cohort study including 28 patients with nonmetastatic colon cancer presenting for elective resection. Included patients had no underlying chronic inflammatory disorders and were not receiving anti-inflammatory drugs.

Disclosures: This study received no funding. No conflict of interests was reported.

Source: Fleming CA et al. JAMA Netw Open. 2021 Aug 30. doi:10.1001/jamanetworkopen.2021.15274.

Key clinical point: Low skeletal muscle area (SMA) and high visceral to total fat ratio were associated with worse outcomes in patients with nonmetastatic colon cancer who presented for elective resection.

Major finding: The risk for 5-year cancer recurrence after surgery was significantly higher in patients with low SMA (hazard ratio [HR], 2.30; P = .04) and high visceral to total fat ratio (HR, 5.78; P = .02). Even the risk of developing a 30-day infective complication was significantly higher in patients with low SMA (odds ratio [OR], 2.13; P = .004) and high visceral to total fat ratio (OR, 3.20; P = .01).

Study details: Findings are from a translational cohort study including 28 patients with nonmetastatic colon cancer presenting for elective resection. Included patients had no underlying chronic inflammatory disorders and were not receiving anti-inflammatory drugs.

Disclosures: This study received no funding. No conflict of interests was reported.

Source: Fleming CA et al. JAMA Netw Open. 2021 Aug 30. doi:10.1001/jamanetworkopen.2021.15274.

Key clinical point: Low skeletal muscle area (SMA) and high visceral to total fat ratio were associated with worse outcomes in patients with nonmetastatic colon cancer who presented for elective resection.

Major finding: The risk for 5-year cancer recurrence after surgery was significantly higher in patients with low SMA (hazard ratio [HR], 2.30; P = .04) and high visceral to total fat ratio (HR, 5.78; P = .02). Even the risk of developing a 30-day infective complication was significantly higher in patients with low SMA (odds ratio [OR], 2.13; P = .004) and high visceral to total fat ratio (OR, 3.20; P = .01).

Study details: Findings are from a translational cohort study including 28 patients with nonmetastatic colon cancer presenting for elective resection. Included patients had no underlying chronic inflammatory disorders and were not receiving anti-inflammatory drugs.

Disclosures: This study received no funding. No conflict of interests was reported.

Source: Fleming CA et al. JAMA Netw Open. 2021 Aug 30. doi:10.1001/jamanetworkopen.2021.15274.

Key clinical point: Patients with metastatic colorectal cancer (mCRC) who initiated trifluridine/tipiracil (FTD/TPI) had better tumor response and disease control than those who initiated regorafenib.

Major finding: Patients who initiated FTD/TPI vs regorafenib as index therapy had better real-world overall response rate (odds ratio [OR], 2.57; 95% confidence interval [CI], 1.38-4.80) and real-world disease control (OR, 2.52; 95% CI, 1.36-4.68). Overall, a similar proportion of patients treated with FTD/TPI and regorafenib discontinued treatment because of disease progression (P = .162), but discontinuation because of toxicity/intolerance was significantly lower with FTD/TPI than regorafenib (8.2% vs 24.2%; P < .001).

Study details: Findings are from a retrospective study of patients with mCRC who initiated FTD/TPI (n=126) or regorafenib (n=95) at a US tertiary oncology center.

Disclosures: This study was funded by Taiho Oncology Inc., Princeton, NJ, USA. No conflict of interests was disclosed.

Source: Patel AK et al. Oncologist. 2021 Aug 18. doi: 10.1002/onco.13942.

Key clinical point: Patients with metastatic colorectal cancer (mCRC) who initiated trifluridine/tipiracil (FTD/TPI) had better tumor response and disease control than those who initiated regorafenib.

Major finding: Patients who initiated FTD/TPI vs regorafenib as index therapy had better real-world overall response rate (odds ratio [OR], 2.57; 95% confidence interval [CI], 1.38-4.80) and real-world disease control (OR, 2.52; 95% CI, 1.36-4.68). Overall, a similar proportion of patients treated with FTD/TPI and regorafenib discontinued treatment because of disease progression (P = .162), but discontinuation because of toxicity/intolerance was significantly lower with FTD/TPI than regorafenib (8.2% vs 24.2%; P < .001).

Study details: Findings are from a retrospective study of patients with mCRC who initiated FTD/TPI (n=126) or regorafenib (n=95) at a US tertiary oncology center.

Disclosures: This study was funded by Taiho Oncology Inc., Princeton, NJ, USA. No conflict of interests was disclosed.

Source: Patel AK et al. Oncologist. 2021 Aug 18. doi: 10.1002/onco.13942.

Key clinical point: Patients with metastatic colorectal cancer (mCRC) who initiated trifluridine/tipiracil (FTD/TPI) had better tumor response and disease control than those who initiated regorafenib.

Major finding: Patients who initiated FTD/TPI vs regorafenib as index therapy had better real-world overall response rate (odds ratio [OR], 2.57; 95% confidence interval [CI], 1.38-4.80) and real-world disease control (OR, 2.52; 95% CI, 1.36-4.68). Overall, a similar proportion of patients treated with FTD/TPI and regorafenib discontinued treatment because of disease progression (P = .162), but discontinuation because of toxicity/intolerance was significantly lower with FTD/TPI than regorafenib (8.2% vs 24.2%; P < .001).

Study details: Findings are from a retrospective study of patients with mCRC who initiated FTD/TPI (n=126) or regorafenib (n=95) at a US tertiary oncology center.

Disclosures: This study was funded by Taiho Oncology Inc., Princeton, NJ, USA. No conflict of interests was disclosed.

Source: Patel AK et al. Oncologist. 2021 Aug 18. doi: 10.1002/onco.13942.

Key clinical point: Rechallenge therapy with cetuximab and avelumab was effective and well tolerated in patients with RAS wild-type metastatic colorectal cancer (mCRC) who experienced a response to first-line antiepidermal growth factor receptor (EGFR) therapy.

Major finding: The trial achieved its primary endpoint with a median overall survival of 11.6 (95% confidence interval [CI], 8.4-14.8) months. Overall, 65% of patients achieved disease control with a median progression-free survival of 3.6 (95% CI, 3.2-4.1) months. Cutaneous eruption (14%) and diarrhea (4%) were the most common grade 3 toxic effects.

Study details: Findings are from a single-arm, phase 2 CAVE trial including 77 patients with RAS wild-type mCRC with a major response to first-line chemotherapy and anti-EGFR drug cetuximab or panitumumab, progressed and further received avelumab+cetuximab until disease progression or unacceptable toxic effects.

Disclosures: This study was supported by Merck and Regione Campania. Some of the authors declared serving as advisor, speaker, and consultant and/or receiving research grants from various sources.

Source: Martinelli E et al. JAMA Oncol. 2021 Aug 12. doi: 10.1001/jamaoncol.2021.2915. 

Key clinical point: Rechallenge therapy with cetuximab and avelumab was effective and well tolerated in patients with RAS wild-type metastatic colorectal cancer (mCRC) who experienced a response to first-line antiepidermal growth factor receptor (EGFR) therapy.

Major finding: The trial achieved its primary endpoint with a median overall survival of 11.6 (95% confidence interval [CI], 8.4-14.8) months. Overall, 65% of patients achieved disease control with a median progression-free survival of 3.6 (95% CI, 3.2-4.1) months. Cutaneous eruption (14%) and diarrhea (4%) were the most common grade 3 toxic effects.

Study details: Findings are from a single-arm, phase 2 CAVE trial including 77 patients with RAS wild-type mCRC with a major response to first-line chemotherapy and anti-EGFR drug cetuximab or panitumumab, progressed and further received avelumab+cetuximab until disease progression or unacceptable toxic effects.

Disclosures: This study was supported by Merck and Regione Campania. Some of the authors declared serving as advisor, speaker, and consultant and/or receiving research grants from various sources.

Source: Martinelli E et al. JAMA Oncol. 2021 Aug 12. doi: 10.1001/jamaoncol.2021.2915. 

Key clinical point: Rechallenge therapy with cetuximab and avelumab was effective and well tolerated in patients with RAS wild-type metastatic colorectal cancer (mCRC) who experienced a response to first-line antiepidermal growth factor receptor (EGFR) therapy.

Major finding: The trial achieved its primary endpoint with a median overall survival of 11.6 (95% confidence interval [CI], 8.4-14.8) months. Overall, 65% of patients achieved disease control with a median progression-free survival of 3.6 (95% CI, 3.2-4.1) months. Cutaneous eruption (14%) and diarrhea (4%) were the most common grade 3 toxic effects.

Study details: Findings are from a single-arm, phase 2 CAVE trial including 77 patients with RAS wild-type mCRC with a major response to first-line chemotherapy and anti-EGFR drug cetuximab or panitumumab, progressed and further received avelumab+cetuximab until disease progression or unacceptable toxic effects.

Disclosures: This study was supported by Merck and Regione Campania. Some of the authors declared serving as advisor, speaker, and consultant and/or receiving research grants from various sources.

Source: Martinelli E et al. JAMA Oncol. 2021 Aug 12. doi: 10.1001/jamaoncol.2021.2915. 

Key clinical point: Findings from this network meta-analysis confirm efficacy and safety of topical Janus kinase (JAK) and phosphodiesterase-4 (PDE4) inhibitors for atopic dermatitis (AD).

Major finding: All included JAK and PDE4 inhibitors, specially tofacitinib 2% twice a day (BID; odds ratio [OR], 19.0; 95% confidence interval [CI], 5.6-77.0), delgocitinib 3% BID (OR, 19.2; 95% CI, 4.6-90.3), and ruxolitinib 1.5% once a day (QD; OR, 13.2; 95% CI, 7.5-25.0), showed higher Investigators Global Assessment response vs placebo. Tofacitinib 2% BID (OR, 0.4; 95% CI, 0.1-1.0) and ruxolitinib 1.5% QD (OR, 0.7; 95% CI, 0.5-1.0) had lower risk for adverse events vs placebo, whereas others showed a comparable safety profile.

Study details: Findings are from a network meta-analysis of 10 randomized controlled trials including 4,689 patients, mostly with mild-to-moderate AD treated with topical JAK and PDE4 inhibitors.

Disclosures: This study was supported by the National Natural Science Foundation of China and the Project for Disciplines of Excellence, West China Hospital. The authors declared no conflict of interests.

Source: Zhang L et al. J Dermatol. 2021 Sep 6. doi: 10.1111/1346-8138.16126.

Key clinical point: Findings from this network meta-analysis confirm efficacy and safety of topical Janus kinase (JAK) and phosphodiesterase-4 (PDE4) inhibitors for atopic dermatitis (AD).

Major finding: All included JAK and PDE4 inhibitors, specially tofacitinib 2% twice a day (BID; odds ratio [OR], 19.0; 95% confidence interval [CI], 5.6-77.0), delgocitinib 3% BID (OR, 19.2; 95% CI, 4.6-90.3), and ruxolitinib 1.5% once a day (QD; OR, 13.2; 95% CI, 7.5-25.0), showed higher Investigators Global Assessment response vs placebo. Tofacitinib 2% BID (OR, 0.4; 95% CI, 0.1-1.0) and ruxolitinib 1.5% QD (OR, 0.7; 95% CI, 0.5-1.0) had lower risk for adverse events vs placebo, whereas others showed a comparable safety profile.

Study details: Findings are from a network meta-analysis of 10 randomized controlled trials including 4,689 patients, mostly with mild-to-moderate AD treated with topical JAK and PDE4 inhibitors.

Disclosures: This study was supported by the National Natural Science Foundation of China and the Project for Disciplines of Excellence, West China Hospital. The authors declared no conflict of interests.

Source: Zhang L et al. J Dermatol. 2021 Sep 6. doi: 10.1111/1346-8138.16126.

Key clinical point: Findings from this network meta-analysis confirm efficacy and safety of topical Janus kinase (JAK) and phosphodiesterase-4 (PDE4) inhibitors for atopic dermatitis (AD).

Major finding: All included JAK and PDE4 inhibitors, specially tofacitinib 2% twice a day (BID; odds ratio [OR], 19.0; 95% confidence interval [CI], 5.6-77.0), delgocitinib 3% BID (OR, 19.2; 95% CI, 4.6-90.3), and ruxolitinib 1.5% once a day (QD; OR, 13.2; 95% CI, 7.5-25.0), showed higher Investigators Global Assessment response vs placebo. Tofacitinib 2% BID (OR, 0.4; 95% CI, 0.1-1.0) and ruxolitinib 1.5% QD (OR, 0.7; 95% CI, 0.5-1.0) had lower risk for adverse events vs placebo, whereas others showed a comparable safety profile.

Study details: Findings are from a network meta-analysis of 10 randomized controlled trials including 4,689 patients, mostly with mild-to-moderate AD treated with topical JAK and PDE4 inhibitors.

Disclosures: This study was supported by the National Natural Science Foundation of China and the Project for Disciplines of Excellence, West China Hospital. The authors declared no conflict of interests.

Source: Zhang L et al. J Dermatol. 2021 Sep 6. doi: 10.1111/1346-8138.16126.

Key clinical point: Patients with atopic dermatitis (AD) were at a higher risk of developing cardiovascular diseases (CVD) and major adverse cardiovascular events (MACEs), independent of metabolic disorders.

Major finding: The risk for CVD (odds ratio [OR], 1.38; 95% confidence interval [CI], 1.34-1.41) and MACEs (OR, 1.40; 95% CI, 1.34-1.45) was significantly higher in patients with vs without AD. The risk for MACEs and CVD was higher in patients without (CVD: OR, 1.25; 95% CI, 1.13-1.39; MACE: OR, 1.22; 95% CI, 1.01-1.47) vs those with (CVD: OR, 1.09; 95% CI, 1.07-1.12; MACE: OR, 1.14; 95% CI, 1.09-1.18) metabolic disorders.

Study details: Findings are from a retrospective analysis of 1,32,460 adult patients with AD matched with 3,97,380 adults without AD.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. The authors declared being investigator, consultant, speaker, current and/or former employees, and stockholders for various sources including Sanofi and/or Regeneron Pharmaceuticals, Inc.

Source: Wu JJ et al. Dermatol Ther (Heidelb). 2021 Aug 27. doi: 10.1007/s13555-021-00587-9.

Key clinical point: Patients with atopic dermatitis (AD) were at a higher risk of developing cardiovascular diseases (CVD) and major adverse cardiovascular events (MACEs), independent of metabolic disorders.

Major finding: The risk for CVD (odds ratio [OR], 1.38; 95% confidence interval [CI], 1.34-1.41) and MACEs (OR, 1.40; 95% CI, 1.34-1.45) was significantly higher in patients with vs without AD. The risk for MACEs and CVD was higher in patients without (CVD: OR, 1.25; 95% CI, 1.13-1.39; MACE: OR, 1.22; 95% CI, 1.01-1.47) vs those with (CVD: OR, 1.09; 95% CI, 1.07-1.12; MACE: OR, 1.14; 95% CI, 1.09-1.18) metabolic disorders.

Study details: Findings are from a retrospective analysis of 1,32,460 adult patients with AD matched with 3,97,380 adults without AD.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. The authors declared being investigator, consultant, speaker, current and/or former employees, and stockholders for various sources including Sanofi and/or Regeneron Pharmaceuticals, Inc.

Source: Wu JJ et al. Dermatol Ther (Heidelb). 2021 Aug 27. doi: 10.1007/s13555-021-00587-9.

Key clinical point: Patients with atopic dermatitis (AD) were at a higher risk of developing cardiovascular diseases (CVD) and major adverse cardiovascular events (MACEs), independent of metabolic disorders.

Major finding: The risk for CVD (odds ratio [OR], 1.38; 95% confidence interval [CI], 1.34-1.41) and MACEs (OR, 1.40; 95% CI, 1.34-1.45) was significantly higher in patients with vs without AD. The risk for MACEs and CVD was higher in patients without (CVD: OR, 1.25; 95% CI, 1.13-1.39; MACE: OR, 1.22; 95% CI, 1.01-1.47) vs those with (CVD: OR, 1.09; 95% CI, 1.07-1.12; MACE: OR, 1.14; 95% CI, 1.09-1.18) metabolic disorders.

Study details: Findings are from a retrospective analysis of 1,32,460 adult patients with AD matched with 3,97,380 adults without AD.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. The authors declared being investigator, consultant, speaker, current and/or former employees, and stockholders for various sources including Sanofi and/or Regeneron Pharmaceuticals, Inc.

Source: Wu JJ et al. Dermatol Ther (Heidelb). 2021 Aug 27. doi: 10.1007/s13555-021-00587-9.

Key clinical point: Patients with atopic dermatitis (AD) were at a significantly higher risk of developing rheumatoid arthritis (RA).

Major finding: Patients with AD had a significantly higher risk for incident RA than patients without AD (pooled odds ratio, 1.30; 95% confidence interval, 1.17-1.44).

Study details: Findings are from a meta-analysis of 4 cohorts and 9 case-control studies.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Rittiphairoj T et al. Dermatitis. 2021 Aug 16. doi: 10.1097/DER.0000000000000781.

Key clinical point: Patients with atopic dermatitis (AD) were at a significantly higher risk of developing rheumatoid arthritis (RA).

Major finding: Patients with AD had a significantly higher risk for incident RA than patients without AD (pooled odds ratio, 1.30; 95% confidence interval, 1.17-1.44).

Study details: Findings are from a meta-analysis of 4 cohorts and 9 case-control studies.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Rittiphairoj T et al. Dermatitis. 2021 Aug 16. doi: 10.1097/DER.0000000000000781.

Key clinical point: Patients with atopic dermatitis (AD) were at a significantly higher risk of developing rheumatoid arthritis (RA).

Major finding: Patients with AD had a significantly higher risk for incident RA than patients without AD (pooled odds ratio, 1.30; 95% confidence interval, 1.17-1.44).

Study details: Findings are from a meta-analysis of 4 cohorts and 9 case-control studies.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Rittiphairoj T et al. Dermatitis. 2021 Aug 16. doi: 10.1097/DER.0000000000000781.

Key clinical point: Dupilumab improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomical regions in pediatric patients.

Major finding: In children, dupilumab improved Eczema Area and Severity Index (EASI) score as early as week 1 in head and neck, trunk, and upper extremities and as early as week 2 in lower extremities. In adolescents, dupilumab improved the EASI score in all anatomical regions as early as week 2. All improvements were sustained through week 16 (all P less than .05).

Study details: Findings are a post hoc analysis of 2 phase 3 dupilumab therapy trials, LIBERTY AD ADOL and LIBERTY AD PEDS, including 167 adolescents with moderate-to-severe AD and 304 children with severe AD inadequately controlled by topical medication.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared receiving grants, honoraria, and/or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees and/or holding stocks/stock of Regeneron Pharmaceuticals or Sanofi Genzyme.

Source: Simpson EL et al. Dermatol Ther (Heidelb). 2021 Aug 24. doi: 10.1007/s13555-021-00568-y.

Key clinical point: Dupilumab improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomical regions in pediatric patients.

Major finding: In children, dupilumab improved Eczema Area and Severity Index (EASI) score as early as week 1 in head and neck, trunk, and upper extremities and as early as week 2 in lower extremities. In adolescents, dupilumab improved the EASI score in all anatomical regions as early as week 2. All improvements were sustained through week 16 (all P less than .05).

Study details: Findings are a post hoc analysis of 2 phase 3 dupilumab therapy trials, LIBERTY AD ADOL and LIBERTY AD PEDS, including 167 adolescents with moderate-to-severe AD and 304 children with severe AD inadequately controlled by topical medication.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared receiving grants, honoraria, and/or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees and/or holding stocks/stock of Regeneron Pharmaceuticals or Sanofi Genzyme.

Source: Simpson EL et al. Dermatol Ther (Heidelb). 2021 Aug 24. doi: 10.1007/s13555-021-00568-y.

Key clinical point: Dupilumab improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomical regions in pediatric patients.

Major finding: In children, dupilumab improved Eczema Area and Severity Index (EASI) score as early as week 1 in head and neck, trunk, and upper extremities and as early as week 2 in lower extremities. In adolescents, dupilumab improved the EASI score in all anatomical regions as early as week 2. All improvements were sustained through week 16 (all P less than .05).

Study details: Findings are a post hoc analysis of 2 phase 3 dupilumab therapy trials, LIBERTY AD ADOL and LIBERTY AD PEDS, including 167 adolescents with moderate-to-severe AD and 304 children with severe AD inadequately controlled by topical medication.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared receiving grants, honoraria, and/or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees and/or holding stocks/stock of Regeneron Pharmaceuticals or Sanofi Genzyme.

Source: Simpson EL et al. Dermatol Ther (Heidelb). 2021 Aug 24. doi: 10.1007/s13555-021-00568-y.